{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:46:15Z","timestamp":1782308775593,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["101034285"],"award-info":[{"award-number":["101034285"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004435","name":"Universidad de Navarra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004435","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13346-025-01984-9","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T15:23:49Z","timestamp":1762442629000},"page":"2316-2330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surface decoration of solid lipid nanoparticles with cyclic RGD peptides for precision therapy in high-risk neuroblastoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Sara","family":"Lorenzoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Aydillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rodr\u00edguez-Nogales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J.","family":"Blanco-Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"1984_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102964","volume":"79","author":"J Nong","year":"2025","unstructured":"Nong J, Su C, Li C, et al. Global, regional, and national epidemiology of childhood neuroblastoma (1990\u20132021): a statistical analysis of incidence, mortality, and DALYs. eClinicalMedicine. 2025;79:102964. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102964.","journal-title":"eClinicalMedicine"},{"key":"1984_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102176","volume":"51","author":"E King","year":"2025","unstructured":"King E, Struck R, Piskareva O. The triad in current neuroblastoma challenges: targeting antigens, enhancing effective cytotoxicity and accurate 3D in vitro modelling. Transl Oncol. 2025;51:102176. https:\/\/doi.org\/10.1016\/j.tranon.2024.102176.","journal-title":"Transl Oncol"},{"issue":"1","key":"1984_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene \u2014 the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19(1):23\u201336. https:\/\/doi.org\/10.1038\/s41571-021-00549-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"1984_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","volume":"14","author":"R van der Meel","year":"2019","unstructured":"van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14(11):1007\u201317. https:\/\/doi.org\/10.1038\/s41565-019-0567-y.","journal-title":"Nat Nanotechnol"},{"key":"1984_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2024.102753","volume":"59","author":"AS Postovalova","year":"2024","unstructured":"Postovalova AS, Tishchenko YA, Istomina MS, et al. Comparison of passive targeted delivery of inorganic and organic nanocarriers among different types of tumors. Nanomedicine. 2024;59:102753. https:\/\/doi.org\/10.1016\/j.nano.2024.102753.","journal-title":"Nanomedicine"},{"key":"1984_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114614","volume":"191","author":"R Sun","year":"2022","unstructured":"Sun R, Xiang J, Zhou Q, et al. The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives. Adv Drug Deliv Rev. 2022;191:114614. https:\/\/doi.org\/10.1016\/j.addr.2022.114614.","journal-title":"Adv Drug Deliv Rev"},{"issue":"23","key":"1984_CR7","doi-asserted-by":"publisher","first-page":"10475","DOI":"10.1021\/acs.jmedchem.9b00511","volume":"62","author":"A Ahmad","year":"2019","unstructured":"Ahmad A, Khan F, Mishra RK, Khan R. Precision cancer nanotherapy: evolving role of multifunctional nanoparticles for cancer active targeting. J Med Chem. 2019;62(23):10475\u201396. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00511.","journal-title":"J Med Chem"},{"issue":"1","key":"1984_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40005-022-00607-6","volume":"53","author":"RK Thapa","year":"2023","unstructured":"Thapa RK, Kim JO. Nanomedicine-based commercial formulations: current developments and future prospects. J Pharm Investig. 2023;53(1):19\u201333. https:\/\/doi.org\/10.1007\/s40005-022-00607-6.","journal-title":"J Pharm Investig"},{"issue":"4875","key":"1984_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.3262922","volume":"242","author":"SE D\u2019Souza","year":"1988","unstructured":"D\u2019Souza SE, Ginsberg MH, Burke TA, Lam SCT, Plow EF. Localization of an Arg-Gly-Asp recognition site within an integrin adhesion receptor. Science. 1988;242(4875):91\u20133. https:\/\/doi.org\/10.1126\/science.3262922.","journal-title":"Science"},{"issue":"1","key":"1984_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"X Pang","year":"2023","unstructured":"Pang X, He X, Qiu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Sig Transduct Target Ther. 2023;8(1):1\u201342. https:\/\/doi.org\/10.1038\/s41392-022-01259-6.","journal-title":"Sig Transduct Target Ther"},{"key":"1984_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","volume":"361","author":"SH El Moukhtari","year":"2023","unstructured":"El Moukhtari SH, Garbayo E, Amundarain A, et al. Lipid nanoparticles for siRNA delivery in cancer treatment. J Control Release. 2023;361:130\u201346. https:\/\/doi.org\/10.1016\/j.jconrel.2023.07.054.","journal-title":"J Control Release"},{"key":"1984_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.addr.2021.03.004","volume":"173","author":"SH El Moukhtari","year":"2021","unstructured":"El Moukhtari SH, Rodr\u00edguez-Nogales C, Blanco-Prieto MJ. Oral lipid nanomedicines: current status and future perspectives in cancer treatment. Adv Drug Deliv Rev. 2021;173:238\u201351. https:\/\/doi.org\/10.1016\/j.addr.2021.03.004.","journal-title":"Adv Drug Deliv Rev"},{"key":"1984_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104709","volume":"86","author":"M Akanda","year":"2023","unstructured":"Akanda M, Mithu MSH, Douroumis D. Solid lipid nanoparticles: an effective lipid-based technology for cancer treatment. J Drug Deliv Sci Technol. 2023;86:104709. https:\/\/doi.org\/10.1016\/j.jddst.2023.104709.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1984_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jconrel.2022.06.010","volume":"348","author":"SH El Moukhtari","year":"2022","unstructured":"El Moukhtari SH, Garbayo E, Fern\u00e1ndez-Teijeiro A, Rodr\u00edguez-Nogales C, Couvreur P, Blanco-Prieto MJ. Nanomedicines and cell-based therapies for embryonal tumors of the nervous system. J Control Release. 2022;348:553\u201371. https:\/\/doi.org\/10.1016\/j.jconrel.2022.06.010.","journal-title":"J Control Release"},{"key":"1984_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121058","volume":"608","author":"R Burgos-Panadero","year":"2021","unstructured":"Burgos-Panadero R, El Moukhtari SH, Noguera I, et al. Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma. Int J Pharm. 2021;608:121058. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.121058.","journal-title":"Int J Pharm"},{"issue":"7","key":"1984_CR16","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3109\/1061186X.2015.1132223","volume":"24","author":"YC Kuo","year":"2016","unstructured":"Kuo YC, Wang IH. Enhanced delivery of etoposide across the blood\u2013brain barrier to restrain brain tumor growth using melanotransferrin antibody- and tamoxifen-conjugated solid lipid nanoparticles. J Drug Target. 2016;24(7):645\u201354. https:\/\/doi.org\/10.3109\/1061186X.2015.1132223.","journal-title":"J Drug Target"},{"issue":"12","key":"1984_CR17","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1016\/j.biomaterials.2011.01.048","volume":"32","author":"YC Kuo","year":"2011","unstructured":"Kuo YC, Liang CT. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials. 2011;32(12):3340\u201350. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.01.048.","journal-title":"Biomaterials"},{"key":"1984_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jtice.2015.12.012","volume":"61","author":"YC Kuo","year":"2016","unstructured":"Kuo YC, Lee IH. Delivery of doxorubicin to glioblastoma multiforme in vitro using solid lipid nanoparticles with surface aprotinin and melanotransferrin antibody for enhanced chemotherapy. J Taiwan Inst Chem Eng. 2016;61:32\u201345. https:\/\/doi.org\/10.1016\/j.jtice.2015.12.012.","journal-title":"J Taiwan Inst Chem Eng"},{"issue":"4","key":"1984_CR19","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.3109\/10717544.2015.1064186","volume":"23","author":"S Song","year":"2016","unstructured":"Song S, Mao G, Du J, Zhu X. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Deliv. 2016;23(4):1404\u20138. https:\/\/doi.org\/10.3109\/10717544.2015.1064186.","journal-title":"Drug Deliv"},{"issue":"5","key":"1984_CR20","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/jps.24388","volume":"104","author":"YC Kuo","year":"2015","unstructured":"Kuo YC, Lee CH. Inhibition against growth of glioblastoma multiforme in vitro using Etoposide-loaded solid lipid nanoparticles with \u03c1-aminophenyl-\u03b1-D-manno-pyranoside and folic acid. J Pharm Sci. 2015;104(5):1804\u201314. https:\/\/doi.org\/10.1002\/jps.24388.","journal-title":"J Pharm Sci"},{"key":"1984_CR21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","volume":"264","author":"C Tapeinos","year":"2017","unstructured":"Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;264:306\u201332. https:\/\/doi.org\/10.1016\/j.jconrel.2017.08.033.","journal-title":"J Control Release"},{"key":"1984_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105924","volume":"98","author":"SM Hosseinikhah","year":"2024","unstructured":"Hosseinikhah SM, Vahdat-Lasemi F, Farhoudi L, Gupta G, Kesharwani P, Sahebkar A. RGD-decorated nanoparticles: therapeutic potential beyond cancer. J Drug Deliv Sci Technol. 2024;98:105924. https:\/\/doi.org\/10.1016\/j.jddst.2024.105924.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1984_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105663","volume":"96","author":"P Kesharwani","year":"2024","unstructured":"Kesharwani P, Chandra J, Karim S, Gupta G, Karwasra R, Sharma A. \u0391v\u03b23 integrin targeting RGD peptide-based nanoparticles as an effective strategy for selective drug delivery to tumor microenvironment. J Drug Deliv Sci Technol. 2024;96:105663. https:\/\/doi.org\/10.1016\/j.jddst.2024.105663.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1984_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/biology10070688","author":"N Li","year":"2021","unstructured":"Li N, Qiu S, Fang Y, Wu J, Li Q. Comparison of linear vs. cyclic RGD pentapeptide interactions with integrin \u03b1v\u03b23 by molecular dynamics simulations. Biology. 2021. https:\/\/doi.org\/10.3390\/biology10070688.","journal-title":"Biology"},{"key":"1984_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2023.104562","volume":"84","author":"M Sanati","year":"2023","unstructured":"Sanati M, Afshari AR, Aminyavari S, Kesharwani P, Jamialahmadi T, Sahebkar A. RGD-engineered nanoparticles as an innovative drug delivery system in cancer therapy. J Drug Deliv Sci Technol. 2023;84:104562. https:\/\/doi.org\/10.1016\/j.jddst.2023.104562.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"46","key":"1984_CR26","doi-asserted-by":"publisher","first-page":"10827","DOI":"10.1016\/j.tet.2005.08.031","volume":"61","author":"CAGN Montalbetti","year":"2005","unstructured":"Montalbetti CAGN, Falque V. Amide bond formation and peptide coupling. Tetrahedron. 2005;61(46):10827\u201352. https:\/\/doi.org\/10.1016\/j.tet.2005.08.031.","journal-title":"Tetrahedron"},{"key":"1984_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jconrel.2018.03.002","volume":"282","author":"L Mart\u00ednez-Jothar","year":"2018","unstructured":"Mart\u00ednez-Jothar L, Doulkeridou S, Schiffelers RM, et al. Insights into maleimide-thiol conjugation chemistry: conditions for efficient surface functionalization of nanoparticles for receptor targeting. J Control Release. 2018;282:101\u20139. https:\/\/doi.org\/10.1016\/j.jconrel.2018.03.002.","journal-title":"J Control Release"},{"issue":"10","key":"1984_CR28","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/S0959-8049(98)00228-7","volume":"34","author":"KR Hande","year":"1998","unstructured":"Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998;34(10):1514\u201321. https:\/\/doi.org\/10.1016\/S0959-8049(98)00228-7.","journal-title":"Eur J Cancer"},{"key":"1984_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120295","volume":"597","author":"N Fine-Shamir","year":"2021","unstructured":"Fine-Shamir N, Beig A, Dahan A. Adequate formulation approach for oral chemotherapy: etoposide solubility, permeability, and overall bioavailability from cosolvent- vs. vitamin E TPGS-based delivery systems. Int J Pharm. 2021;597:120295. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120295.","journal-title":"Int J Pharm"},{"key":"1984_CR30","doi-asserted-by":"publisher","unstructured":"Estella-Hermoso de Mendoza A, Rayo M, Mollinedo F, Blanco-Prieto MJ. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization. Eur J Pharmaceut Biopharmaceut. 2008;68(2):207\u2013213. https:\/\/doi.org\/10.1016\/j.ejpb.2007.06.015.","DOI":"10.1016\/j.ejpb.2007.06.015."},{"issue":"8","key":"1984_CR31","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1007\/s13346-023-01466-w","volume":"14","author":"SHE Moukhtari","year":"2024","unstructured":"Moukhtari SHE, Mu\u00f1oz-Juan A, Del Campo-Montoya R, Laromaine A, Blanco-Prieto MJ. Biosafety evaluation of etoposide lipid nanomedicines in C. elegans. Drug Deliv Transl Res. 2024;14(8):2158\u201369. https:\/\/doi.org\/10.1007\/s13346-023-01466-w.","journal-title":"Drug Deliv Transl Res"},{"key":"1984_CR32","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jconrel.2023.01.063","volume":"354","author":"TG Agnihotri","year":"2023","unstructured":"Agnihotri TG, Alexander A, Agrawal M, Dubey SK, Jain A. In vitro-in vivo correlation in nanocarriers: from protein corona to therapeutic implications. J Control Release. 2023;354:794\u2013809. https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.063.","journal-title":"J Control Release"},{"issue":"7","key":"1984_CR33","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s11095-006-0284-8","volume":"23","author":"P Couvreur","year":"2006","unstructured":"Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res. 2006;23(7):1417\u201350. https:\/\/doi.org\/10.1007\/s11095-006-0284-8.","journal-title":"Pharm Res"},{"key":"1984_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2025.137334","volume":"691","author":"H Wang","year":"2025","unstructured":"Wang H, Pestre H, Tan EKN, et al. Facile lipid nanoparticle size engineering approach via controllable fusion induced by depletion forces. J Colloid Interface Sci. 2025;691:137334. https:\/\/doi.org\/10.1016\/j.jcis.2025.137334.","journal-title":"J Colloid Interface Sci"},{"issue":"9","key":"1984_CR35","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1016\/j.xphs.2023.07.002","volume":"112","author":"HW Chan","year":"2023","unstructured":"Chan HW, Chow S, Zhang X, Kwok PCL, Chow SF. Role of particle size in translational research of nanomedicines for successful drug delivery: discrepancies and inadequacies. J Pharm Sci. 2023;112(9):2371\u201384. https:\/\/doi.org\/10.1016\/j.xphs.2023.07.002.","journal-title":"J Pharm Sci"},{"key":"1984_CR36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jconrel.2018.02.013","volume":"275","author":"JB Coty","year":"2018","unstructured":"Coty JB, Vauthier C. Characterization of nanomedicines: a reflection on a field under construction needed for clinical translation success. J Control Release. 2018;275:254\u201368. https:\/\/doi.org\/10.1016\/j.jconrel.2018.02.013.","journal-title":"J Control Release"},{"issue":"8","key":"1984_CR37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nrd2591","volume":"9","author":"RA Petros","year":"2010","unstructured":"Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615\u201327. https:\/\/doi.org\/10.1038\/nrd2591.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"1984_CR38","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2174\/187152010794728639","volume":"10","author":"C Mas-Moruno","year":"2010","unstructured":"Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010;10(10):753\u201368. https:\/\/doi.org\/10.2174\/187152010794728639.","journal-title":"Anticancer Agents Med Chem"},{"issue":"10","key":"1984_CR39","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S1470-2045(14)70403-6","volume":"15","author":"OL Chinot","year":"2014","unstructured":"Chinot OL. Cilengitide in glioblastoma: when did it fail? Lancet Oncol. 2014;15(10):1044\u20135. https:\/\/doi.org\/10.1016\/S1470-2045(14)70403-6.","journal-title":"Lancet Oncol"},{"issue":"32","key":"1984_CR40","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.1021\/ja9603721","volume":"118","author":"R Haubner","year":"1996","unstructured":"Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin \u03b1V\u03b23 antagonists. J Am Chem Soc. 1996;118(32):7461\u201372. https:\/\/doi.org\/10.1021\/ja9603721.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"1984_CR41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1021\/bc00031a015","volume":"6","author":"N Nakajima","year":"1995","unstructured":"Nakajima N, Ikada Y. Mechanism of amide formation by carbodiimide for bioconjugation in aqueous media. Bioconjug Chem. 1995;6(1):123\u201330. https:\/\/doi.org\/10.1021\/bc00031a015.","journal-title":"Bioconjug Chem"},{"issue":"11","key":"1984_CR42","doi-asserted-by":"publisher","first-page":"2304378","DOI":"10.1002\/smll.202304378","volume":"20","author":"MM Billingsley","year":"2024","unstructured":"Billingsley MM, Gong N, Mukalel AJ, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small. 2024;20(11):2304378. https:\/\/doi.org\/10.1002\/smll.202304378.","journal-title":"Small"},{"key":"1984_CR43","doi-asserted-by":"publisher","unstructured":"Yadav RN, Srivastava AK, Banik BK. 10 - One-pot strategy: A highly economical tool in organic synthesis and medicinal chemistry. In: Banik BK, ed. Green Approaches in Medicinal Chemistry for Sustainable Drug Design. Advances in Green and Sustainable Chemistry. Elsevier; 2020:353\u2013425. https:\/\/doi.org\/10.1016\/B978-0-12-817592-7.00010-1.","DOI":"10.1016\/B978-0-12-817592-7.00010-1."},{"issue":"7","key":"1984_CR44","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1021\/acs.molpharmaceut.1c00037","volume":"18","author":"C Doyen","year":"2021","unstructured":"Doyen C, Larquet E, Coureux PD, et al. Nuclear magnetic resonance spectroscopy: a multifaceted toolbox to probe structure, dynamics, interactions, and real-time in situ release kinetics in peptide-liposome formulations. Mol Pharm. 2021;18(7):2521\u201339. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00037.","journal-title":"Mol Pharm"},{"issue":"19","key":"1984_CR45","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.2217\/nnm.15.138","volume":"10","author":"DC Baiu","year":"2015","unstructured":"Baiu DC, Artz NS, McElreath MR, et al. High specificity targeting and detection of human neuroblastoma using multifunctional anti-GD2 iron-oxide nanoparticles. Nanomedicine (Lond). 2015;10(19):2973\u201388. https:\/\/doi.org\/10.2217\/nnm.15.138.","journal-title":"Nanomedicine (Lond)"},{"issue":"3","key":"1984_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1200\/JCO.20.01892","volume":"39","author":"IY Cheung","year":"2021","unstructured":"Cheung IY, Cheung NKV, Modak S, et al. Survival impact of anti-GD2 antibody response in a phase II ganglioside vaccine trial among patients with high-risk neuroblastoma with prior disease progression. J Clin Oncol. 2021;39(3):215\u201326. https:\/\/doi.org\/10.1200\/JCO.20.01892.","journal-title":"J Clin Oncol"},{"key":"1984_CR47","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.omtn.2021.08.021","volume":"26","author":"L Zhang","year":"2021","unstructured":"Zhang L, Wang M, Zhu Z, et al. A GD2-aptamer-mediated, self-assembling nanomedicine for targeted multiple treatments in neuroblastoma theranostics. Mol Ther. 2021;26:732\u201348. https:\/\/doi.org\/10.1016\/j.omtn.2021.08.021.","journal-title":"Mol Ther"},{"issue":"1","key":"1984_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-13-65","volume":"13","author":"Q Zhu","year":"2013","unstructured":"Zhu Q, Feng C, Liao W, Zhang Y, Tang S. Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model. Cancer Cell Int. 2013;13(1):65. https:\/\/doi.org\/10.1186\/1475-2867-13-65.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1984_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10238-025-01724-w","volume":"25","author":"A Bayani","year":"2025","unstructured":"Bayani A, Abosaoda MK, Rizaev J, Nazari M, Jafari Z, Soleimani SH. Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy. Clin Exp Med. 2025;25(1):1\u201314. https:\/\/doi.org\/10.1007\/s10238-025-01724-w.","journal-title":"Clin Exp Med"},{"issue":"8","key":"1984_CR50","doi-asserted-by":"publisher","first-page":"9457","DOI":"10.1021\/acsami.0c18846","volume":"13","author":"F Gao","year":"2021","unstructured":"Gao F, Zhou J, Sun Y, et al. Programmable repurposing of existing drugs as pharmaceutical elements for the construction of aptamer-drug conjugates. ACS Appl Mater Interfaces. 2021;13(8):9457\u201363. https:\/\/doi.org\/10.1021\/acsami.0c18846.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"5","key":"1984_CR51","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1021\/nn301869z","volume":"6","author":"Z Xiao","year":"2012","unstructured":"Xiao Z, Farokhzad OC. Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. ACS Nano. 2012;6(5):3670\u20136. https:\/\/doi.org\/10.1021\/nn301869z.","journal-title":"ACS Nano"},{"issue":"10","key":"1984_CR52","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.1007\/s12274-018-2083-z","volume":"11","author":"DM Valcourt","year":"2018","unstructured":"Valcourt DM, Harris J, Riley RS, Dang M, Wang J, Day ES. Advances in targeted nanotherapeutics: from bioconjugation to biomimicry. Nano Res. 2018;11(10):4999\u20135016. https:\/\/doi.org\/10.1007\/s12274-018-2083-z.","journal-title":"Nano Res"},{"issue":"9","key":"1984_CR53","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3390\/pharmaceutics14091827","volume":"14","author":"A Margari","year":"2022","unstructured":"Margari A, Monteduro AG, Rizzato S, et al. The encapsulation of Citicoline within solid lipid nanoparticles enhances its capability to counteract the 6-Hydroxydopamine-induced cytotoxicity in human neuroblastoma SH-SY5Y cells. Pharmaceutics. 2022;14(9):1827. https:\/\/doi.org\/10.3390\/pharmaceutics14091827.","journal-title":"Pharmaceutics"},{"key":"1984_CR54","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.actbio.2023.05.030","volume":"166","author":"J Zhang","year":"2023","unstructured":"Zhang J, Wang B, Wang H, et al. Reversibly \u201cdouble locked\u201d hydroxycamptothecin prodrug nanoparticles for targeted chemotherapy of lung cancer. Acta Biomater. 2023;166:593\u2013603. https:\/\/doi.org\/10.1016\/j.actbio.2023.05.030.","journal-title":"Acta Biomater"},{"issue":"1","key":"1984_CR55","doi-asserted-by":"publisher","first-page":"14505","DOI":"10.1038\/s41598-020-71396-x","volume":"10","author":"JM Rios De La Rosa","year":"2020","unstructured":"Rios De La Rosa JM, Spadea A, Donno R, et al. Microfluidic-assisted preparation of RGD-decorated nanoparticles: exploring integrin-facilitated uptake in cancer cell lines. Sci Rep. 2020;10(1):14505. https:\/\/doi.org\/10.1038\/s41598-020-71396-x.","journal-title":"Sci Rep"},{"key":"1984_CR56","doi-asserted-by":"publisher","first-page":"9447","DOI":"10.2147\/IJN.S274289","volume":"15","author":"X Wang","year":"2020","unstructured":"Wang X, Qiu Y, Wang M, et al. Endocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy. Int J Nanomedicine. 2020;15:9447\u201367. https:\/\/doi.org\/10.2147\/IJN.S274289.","journal-title":"Int J Nanomedicine"},{"key":"1984_CR57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.biomaterials.2018.07.006","volume":"180","author":"X Song","year":"2018","unstructured":"Song X, Li R, Deng H, et al. Receptor mediated transcytosis in biological barrier: the influence of receptor character and their ligand density on the transmembrane pathway of active-targeting nanocarriers. Biomaterials. 2018;180:78\u201390. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.07.006.","journal-title":"Biomaterials"},{"key":"1984_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01854-x","author":"J Zhang","year":"2023","unstructured":"Zhang J, Sun J, Li C, Qiao H, Hussain Z. Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer. J Nanobiotechnology. 2023. https:\/\/doi.org\/10.1186\/s12951-023-01854-x.","journal-title":"J Nanobiotechnology"},{"key":"1984_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.17179\/excli2015-561","volume":"14","author":"A Montecucco","year":"2015","unstructured":"Montecucco A, Zanetta F, Biamonti G. Molecular mechanisms of etoposide. EXCLI J. 2015;14:95\u2013108. https:\/\/doi.org\/10.17179\/excli2015-561.","journal-title":"EXCLI J"},{"issue":"2","key":"1984_CR60","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s10495-009-0440-9","volume":"15","author":"I Schonn","year":"2010","unstructured":"Schonn I, Hennesen J, Dartsch DC. Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage. Apoptosis. 2010;15(2):162\u201372. https:\/\/doi.org\/10.1007\/s10495-009-0440-9.","journal-title":"Apoptosis"},{"issue":"5","key":"1984_CR61","doi-asserted-by":"publisher","first-page":"e63583","DOI":"10.1371\/journal.pone.0063583","volume":"8","author":"GKY Chan","year":"2013","unstructured":"Chan GKY, Kleinheinz TL, Peterson D, Moffat JG. A simple high-content cell cycle assay reveals frequent discrepancies between cell number and ATP and MTS proliferation assays. PLoS ONE. 2013;8(5):e63583. https:\/\/doi.org\/10.1371\/journal.pone.0063583.","journal-title":"PLoS ONE"},{"issue":"4","key":"1984_CR62","doi-asserted-by":"publisher","first-page":"485","DOI":"10.14670\/HH-25.485","volume":"25","author":"C Nam","year":"2010","unstructured":"Nam C, Doi K, Nakayama H. Etoposide induces G2\/M arrest and apoptosis in neural progenitor cells via DNA damage and an ATM\/p53-related pathway. Histol Histopathol. 2010;25(4):485\u201393. https:\/\/doi.org\/10.14670\/HH-25.485.","journal-title":"Histol Histopathol"},{"key":"1984_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-015-0086-4","volume":"13","author":"B Wang","year":"2015","unstructured":"Wang B, Yu XC, Xu SF, Xu M. Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma. J Nanobiotechnology. 2015;13:22. https:\/\/doi.org\/10.1186\/s12951-015-0086-4.","journal-title":"J Nanobiotechnology"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01984-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01984-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01984-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:49:49Z","timestamp":1782305389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01984-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1984"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01984-9","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}